Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years - Takeaways - MDSpire

Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years

  • By

  • Shi Hao Ernest Koh

  • Wenting Huang

  • Eric W. Hall

  • Jeb Jones

  • Xiao Zang

  • Courtney R. Yarbrough

  • Edwin E. Corbin-Gutierrez

  • Patrick S. Sullivan

  • Aaron J. Siegler

  • June 26, 2026

  • 0 min

Share

  • 1

    LAI cabotegravir (CAB) was approved as the first long-acting injectable pre-exposure prophylaxis (LAI-PrEP) in December 2021.

  • 2

    By the end of 2023, LAI-CAB accounted for only 2.5% of US PrEP users despite high interest and preference for it over oral PrEP.

  • 3

    Barriers to LAI-CAB uptake include medication acquisition challenges, logistical issues, and complex insurance processes.

  • 4

    The study utilized deidentified commercial medical and pharmacy claims data from 2022 to 2024 to analyze LAI-CAB and oral PrEP use.

  • 5

    Persistence in LAI-CAB use was defined as having at least 2 doses in each biannual period, reflecting ongoing engagement in care.

Original Source(s)

Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years

  • by Shi Hao Ernest Koh, Wenting Huang, Eric W. Hall, Jeb Jones, Xiao Zang, Courtney R. Yarbrough, Edwin E. Corbin-Gutierrez, Patrick S. Sullivan, Aaron J. Siegler

  • June 26, 2026

Related Content

Association of antiretroviral therapy regimens with serum cortisol abnormalities in people living with HIV/AIDS: a retrospective study

N-Myc and STAT interactor as a context-dependent switch in innate antiviral immunity

Peak-MELD scores, a disease trajectory associated with reduced access to liver transplantation